OTCMKTS:SWTUY SWEDISH ORPHAN/S (SWTUY) Stock Price, News & Analysis $24.38 -0.29 (-1.18%) As of 04/9/2019 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About SWEDISH ORPHAN/S Stock (OTCMKTS:SWTUY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SWEDISH ORPHAN/S alerts:Sign Up Key Stats Today's Range$24.38▼$24.3850-Day Range$24.38▼$24.3852-Week Range$18.50▼$31.96Volume200 shsAverage Volume1,665 shsMarket Capitalization$6.64 billionP/E Ratio48.76Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden. Read More Receive SWTUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SWEDISH ORPHAN/S and its competitors with MarketBeat's FREE daily newsletter. Email Address SWTUY Stock News HeadlinesSwedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’July 16, 2025 | bloomberg.comSwedish Orphan Biovitrum AB: Sobi and Apellis: Aspaveli/Empaveli Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney DiseasesJune 6, 2025 | finanznachrichten.deA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 30 at 2:00 AM | Porter & Company (Ad)Swedish Orphan Biovitrum AB: Sobi to share new clinical data and research at EULAR 2025May 28, 2025 | finanznachrichten.deBerenberg cuts SOBI stock target to SEK360, maintains buyApril 18, 2025 | uk.investing.comRBC Capital Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)January 14, 2025 | markets.businessinsider.comSobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune ThrombocytopeniaDecember 12, 2024 | markets.businessinsider.comSobi North America Says SNDA Accepted For Avatrombopag In Paediatric Immune ThrombocytopeniaDecember 12, 2024 | markets.businessinsider.comSee More Headlines SWTUY Stock Analysis - Frequently Asked Questions How have SWTUY shares performed this year? SWEDISH ORPHAN/S's stock was trading at $24.38 at the beginning of 2025. Since then, SWTUY shares have increased by 0.0% and is now trading at $24.38. How do I buy shares of SWEDISH ORPHAN/S? Shares of SWTUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:SWTUY Previous SymbolNASDAQ:SWTUY CIKN/A Webwww.sobi.com Phone46-0-869-720-00FaxN/AEmployees902Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.50 Trailing P/E Ratio48.76 Forward P/E RatioN/A P/E Growth1.3Net Income$134.73 million Net Margins25.75% Pretax MarginN/A Return on Equity29.63% Return on Assets18.74% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$763.19 million Price / Sales8.71 Cash Flow$0.70 per share Price / Cash Flow34.66 Book Value$2.88 per share Price / Book8.47Miscellaneous Outstanding Shares272,508,000Free FloatN/AMarket Cap$6.64 billion OptionableNot Optionable Beta1.81 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:SWTUY) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredSomething BIG is about to hit the stock marketMost investors won’t see it coming—but Weiss Ratings says a major market event is brewing. Their system jus...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SWEDISH ORPHAN/S Please log in to your account or sign up in order to add this asset to your watchlist. Share SWEDISH ORPHAN/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.